ES2132101T3 - Procedimiento para la preparacion de un medicamento destinado a la administracion por via oral o topica en el tratamiento de leishmaniasis. - Google Patents

Procedimiento para la preparacion de un medicamento destinado a la administracion por via oral o topica en el tratamiento de leishmaniasis.

Info

Publication number
ES2132101T3
ES2132101T3 ES92116415T ES92116415T ES2132101T3 ES 2132101 T3 ES2132101 T3 ES 2132101T3 ES 92116415 T ES92116415 T ES 92116415T ES 92116415 T ES92116415 T ES 92116415T ES 2132101 T3 ES2132101 T3 ES 2132101T3
Authority
ES
Spain
Prior art keywords
group
oral
treatment
administration
leishmaniasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92116415T
Other languages
English (en)
Inventor
Hansjorg Prof Dr Eibl
Clemens Dr Unger
Jurgen Prof Dr Engel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Asta Medica GmbH
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica GmbH, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Asta Medica GmbH
Application granted granted Critical
Publication of ES2132101T3 publication Critical patent/ES2132101T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCION CONCIERNE A UN NUEVO MEDICAMENTO PARA LA ADMINISTRACION ORAL O TOPICA, EN EL TRATAMIENTO DE ENFERMEDADES PRODUCIDAS POR PROTOZOOS, ESPECIALMENTE DE LA LEISHMANIOSIS, QUE COMO SUSTANCIA ACTIVA TIENE UNO O VARIOS COMPUESTOS DE FORMULA GENERAL (I), DONDE R1 ES UN RESTO HIDROCARBURO, SATURADO O INSATURADO UNA O VARIAS VECES, CON 12 A 20 ATOMOS DE C, Y R2, R3 Y R4 SON, INDEPENDIENTES UNO DEL OTRO, HIDROGENO, UN GRUPO C1 C5 HIDROXIALQUILO, POR EL QUE DOS DE LOS RESTOS R2, R3 Y R4, UNO CON OTRO, PUEDEN FORMAR UN GRUPO C2 ADO EL CASO PUEDE SER SUSTITUIDO CON UN GRUPO R5 -, DONDE R5 ES HIDROGENO, UN GRUPO C1 UPO C3 C6 ASI COMO DADO EL CASO EL CONTENIDO USUAL DE SUSTANCIAS DE RELLENO FARMACEUTICAS Y/O SUSTANCIAS AUXILIARES, DILUYENTES Y PORTADORAS.
ES92116415T 1991-09-27 1992-09-24 Procedimiento para la preparacion de un medicamento destinado a la administracion por via oral o topica en el tratamiento de leishmaniasis. Expired - Lifetime ES2132101T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4132344A DE4132344A1 (de) 1991-09-27 1991-09-27 Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Publications (1)

Publication Number Publication Date
ES2132101T3 true ES2132101T3 (es) 1999-08-16

Family

ID=6441697

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92116415T Expired - Lifetime ES2132101T3 (es) 1991-09-27 1992-09-24 Procedimiento para la preparacion de un medicamento destinado a la administracion por via oral o topica en el tratamiento de leishmaniasis.

Country Status (12)

Country Link
US (1) US5980915A (es)
EP (1) EP0534445B1 (es)
JP (2) JP3587862B2 (es)
KR (2) KR100270255B1 (es)
AT (1) ATE177950T1 (es)
BR (1) BR9203768A (es)
DE (2) DE4132344A1 (es)
DK (1) DK0534445T3 (es)
ES (1) ES2132101T3 (es)
GR (1) GR3030016T3 (es)
MX (1) MX9205466A (es)
SG (1) SG49692A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254879B1 (en) * 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
US5681829A (en) * 1992-10-08 1997-10-28 Shaman Pharmaceuticals, Inc. Class of phosphocholine derivatives having antifungal activity
DE4305552A1 (de) * 1992-12-18 1994-06-23 Rhone Poulenc Rorer Gmbh Verwendung von Alkanolaminen
ES2175663T3 (es) * 1998-01-22 2002-11-16 Zentaris Ag Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
RU2190390C2 (ru) * 1998-01-22 2002-10-10 Центарис АГ Твердая фармацевтическая композиция для орального введения при лечении лейшманиоза и способ ее производства, фармацевтическая комбинация для лечения лейшманиоза у млекопитающих и способ лечения (варианты)
DE19835611A1 (de) 1998-08-06 2000-02-10 Max Planck Gesellschaft Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
DE10025124B4 (de) * 2000-05-20 2015-07-16 Beiersdorf Ag Kombinationen von Glycerinmonoalkylethern und Aryl-substituierten Alkoholen
DE10025122A1 (de) * 2000-05-20 2001-11-22 Beiersdorf Ag Kombinationen von Clycerinmonoalkylethern und Fettsäreglyceriden
BG64968B1 (bg) * 2000-08-07 2006-11-30 Asta Medica Aktiengesellschaft Твърди фармацевтични състави, съдържащи милтефозин за орално приложение при лечението на leishmaniasis
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
US8097752B2 (en) * 2002-10-30 2012-01-17 Makscientific, Llc Antiprotozoal ring-substituted phospholipids
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
US20070167408A1 (en) * 2005-12-19 2007-07-19 Zentaris Gmbh Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
EP1962862B1 (en) * 2005-12-19 2013-09-04 Æterna Zentaris GmbH Alkyl phospholipid derivatives with reduced cytotoxicity and uses therof
DE102007014375A1 (de) * 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oleylphosphocholin
AU2009349348B2 (en) 2009-07-09 2014-09-11 Paul Meng Liquid pharmaceutical form of alkylphosphocholine and method of preparing same
CA2818194A1 (en) 2010-11-22 2012-05-31 Dafra Pharma Research&Development Bvba Solid dosage forms of oleyl phosphocholine
SI3773544T1 (sl) * 2018-04-10 2026-01-30 Cellectar Biosciences, Inc. Fosfolipid-flavaglin konjugati ter postopki njihove uporabe za ciljno zdravljenje raka
JP7631329B2 (ja) 2019-10-10 2025-02-18 セレクター・バイオサイエンシズ・インコーポレイテッド リン脂質－フラバグリン抱合体及び標的化されたがん治療のためのリン脂質－フラバグリン抱合体の使用方法
JP7738404B2 (ja) * 2021-04-26 2025-09-12 株式会社アルビオン 水中油型乳化組成物
CN119798052B (zh) * 2025-01-02 2025-11-04 万华化学集团股份有限公司 一种非离子型表面活性剂及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
IE59778B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicament with anti-tumour action containing hexadecylphosphocholine
US5087721A (en) * 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
DE58904595D1 (de) * 1988-04-19 1993-07-15 Hafslund Nycomed Pharma Neue alkylphosphonoserine, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel.

Also Published As

Publication number Publication date
JP2004315540A (ja) 2004-11-11
US5980915A (en) 1999-11-09
BR9203768A (pt) 1993-04-20
KR100283783B1 (ko) 2001-02-15
SG49692A1 (en) 1998-06-15
MX9205466A (es) 1993-05-01
HK1004472A1 (en) 1998-11-27
ATE177950T1 (de) 1999-04-15
EP0534445A1 (de) 1993-03-31
KR930005622A (ko) 1993-04-20
DE4132344A1 (de) 1993-04-01
GR3030016T3 (en) 1999-07-30
DK0534445T3 (da) 1999-10-18
EP0534445B1 (de) 1999-03-24
JP3587862B2 (ja) 2004-11-10
KR100270255B1 (ko) 2002-09-04
JPH06263643A (ja) 1994-09-20
DE59209663D1 (de) 1999-04-29

Similar Documents

Publication Publication Date Title
AR029463A1 (es) Pirrolidinas disustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
ES2159591T3 (es) Composicion de liberacion controlada.
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
AR028988A1 (es) Derivados amida, proceso para su preparacion, composicion farmaceutica que los comprende, y su uso en la fabricacion de un medicamento util en el tratamiento de enfermedades o afecciones clinicas mediadas por citoquinas
AR025959A1 (es) DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
ES2175415T3 (es) Inhibidores de metaloproteasas matriciales basados en fosfinato.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
ES2096150T3 (es) Copolimeros vinilicos reticulados, procedimiento para su preparacion, asi como el empleo de estos compuestos.
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
DE69531098D1 (de) Piperidine und pyrrolidine
ES2038359T3 (es) Procedimiento para la obtencion de formulaciones inyectables intramusculares de inhibidores de girasa.
ES2126114T3 (es) Composiciones liquidas estables de interferon gamma.
ES2043696T3 (es) Derivados de prostaglandina e1 (derivados-pge1) como substancias activas farmaceuticas y medicamentos que contienen estos compuestos, especialmente para aplicacion transcutanea.
FR2378026A1 (fr) Medicaments contenant des derives de sulfure d'hydroxymethyl-2 amino-2' diphenyle
SE8600658D0 (sv) Novel composition of matter
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 534445

Country of ref document: ES